Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2017; 38(05): 585-595
DOI: 10.1055/s-0037-1606201
DOI: 10.1055/s-0037-1606201
Review Article
Genetics of Pulmonary Arterial Hypertension
Further Information
Publication History
Publication Date:
15 October 2017 (online)
Abstract
Tremendous progress has been made in understanding the genetics of pulmonary arterial hypertension (PAH) since its description in the 1950s as a primary disorder of the pulmonary vasculature. Heterozygous germline mutations in the gene coding bone morphogenetic receptor type 2 (BMPR2) are detectable in the majority of cases of heritable PAH, and in approximately 20% of cases of idiopathic pulmonary arterial hypertension (IPAH). However, recent advances in gene discovery methods have facilitated the discovery of additional genes with mutations among those with and without familial PAH. Heritable PAH is an autosomal dominant disease characterized by reduced penetrance, variable expressivity, and female predominance. Biallelic germline mutations in the gene EIF2AK4 are now associated with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Growing genetic knowledge enhances our capacity to pursue and provide genetic counseling, although the issue remains complex given that the majority of carriers of PAH-related mutations will never be diagnosed with the disease.
-
References
- 1 Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951; 11 (06) 686-705
- 2 Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 1954; 30 (03) 195-207
- 3 Simonneau G, Gatzoulis MA, Adatia I. , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D34-D41
- 4 Loyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 1984; 129 (01) 194-197
- 5 Soubrier F, Chung WK, Machado R. , et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D13-D21
- 6 Rich S, Dantzker DR, Ayres SM. , et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107 (02) 216-223
- 7 Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95 (12) 2603-2606
- 8 Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG. Familial primary pulmonary hypertension locus mapped to chromosome 2q31-q32. Chest 1998; 114 (1, Suppl): 57S-58S
- 9 Thomson JR, Machado RD, Pauciulo MW. , et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37 (10) 741-745
- 10 Lane KB, Machado RD, Pauciulo MW. , et al; International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26 (01) 81-84
- 11 Machado RD, Southgate L, Eichstaedt CA. , et al. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. Hum Mutat 2015; 36 (12) 1113-1127
- 12 Evans JD, Girerd B, Montani D. , et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 2016; 4 (02) 129-137
- 13 Trembath RC, Thomson JR, Machado RD. , et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345 (05) 325-334
- 14 Harrison RE, Flanagan JA, Sankelo M. , et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003; 40 (12) 865-871
- 15 Drake KM, Comhair SA, Erzurum SC, Tuder RM, Aldred MA. Endothelial chromosome 13 deletion in congenital heart disease-associated pulmonary arterial hypertension dysregulates SMAD9 signaling. Am J Respir Crit Care Med 2015; 191 (07) 850-854
- 16 Drake KM, Dunmore BJ, McNelly LN, Morrell NW, Aldred MA. Correction of nonsense BMPR2 and SMAD9 mutations by Ataluren in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013; 49 (03) 403-409
- 17 Nasim MT, Ogo T, Ahmed M. , et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011; 32 (12) 1385-1389
- 18 Tang H, Desai AA, Yuan JX. ; Application of Whole-Exome Sequencing to the Study of Pathogenic Mechanisms. Genetic insights into pulmonary arterial hypertension. Am J Respir Crit Care Med 2016; 194 (04) 393-397
- 19 Austin ED, Ma L, LeDuc C. , et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012; 5 (03) 336-343
- 20 Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Caveolae and signalling in cancer. Nat Rev Cancer 2015; 15 (04) 225-237
- 21 Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8 (03) 185-194
- 22 Maniatis NA, Shinin V, Schraufnagel DE. , et al. Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1-/- mice. Am J Physiol Lung Cell Mol Physiol 2008; 294 (05) L865-L873
- 23 Zhao YY, Malik AB. A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation. Trends Cardiovasc Med 2009; 19 (07) 238-242
- 24 Zhao YY, Zhao YD, Mirza MK. , et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 2009; 119 (07) 2009-2018
- 25 Achcar RO, Demura Y, Rai PR. , et al. Loss of Caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006; 129 (03) 696-705
- 26 Zhao YY, Liu Y, Stan RV. , et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A 2002; 99 (17) 11375-11380
- 27 Wang KY, Lee MF, Ho HC. , et al. Serum caveolin-1 as a novel biomarker in idiopathic pulmonary artery hypertension. BioMed Res Int 2015; 2015: 173970
- 28 Han B, Copeland CA, Kawano Y. , et al. Characterization of a caveolin-1 mutation associated with both pulmonary arterial hypertension and congenital generalized lipodystrophy. Traffic 2016; 17 (12) 1297-1312
- 29 Ma L, Roman-Campos D, Austin ED. , et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013; 369 (04) 351-361
- 30 Higasa K, Ogawa A, Terao C. , et al. A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension. BMC Pulm Med 2017; 17 (01) 57
- 31 Navas P, Tenorio J, Quezada CA. , et al. Molecular analysis of BMPR2, TBX4, and KCNK3 and genotype-phenotype correlations in Spanish patients and families with idiopathic and hereditary pulmonary arterial hypertension. Rev Esp Cardiol (Engl Ed) 2016; 69 (11) 1011-1019
- 32 Navas Tejedor P, Tenorio Castaño J, Palomino Doza J. , et al. An homozygous mutation in KCNK3 is associated with an aggressive form of hereditary pulmonary arterial hypertension. Clin Genet 2017; 91 (03) 453-457
- 33 Antigny F, Hautefort A, Meloche J. , et al. Potassium channel subfamily K member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation 2016; 133 (14) 1371-1385
- 34 Kerstjens-Frederikse WS, Bongers EM, Roofthooft MT. , et al. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. J Med Genet 2013; 50 (08) 500-506
- 35 de Jesus Perez VA, Yuan K, Lyuksyutova MA. , et al. Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 189 (10) 1260-1272
- 36 Montani D, Lau EM, Dorfmüller P. , et al. Pulmonary veno-occlusive disease. Eur Respir J 2016; 47 (05) 1518-1534
- 37 Montani D, Achouh L, Dorfmüller P. , et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87 (04) 220-233
- 38 Montani D, Price LC, Dorfmuller P. , et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33 (01) 189-200
- 39 Eyries M, Montani D, Girerd B. , et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46 (01) 65-69
- 40 Best DH, Sumner KL, Austin ED. , et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest 2014; 145 (02) 231-236
- 41 Montani D, Girerd B, Jaïs X. , et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017; 5 (02) 125-134
- 42 Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012; 11 (10) 790-811
- 43 Feng F, Harper RL, Reynolds PN. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling. Respirology 2016; 21 (03) 526-532
- 44 Larkin EK, Newman JH, Austin ED. , et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186 (09) 892-896
- 45 Girerd B, Montani D, Eyries M. , et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010; 11: 73
- 46 Austin ED, Phillips JA, Cogan JD. , et al. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res 2009; 10: 87
- 47 Rosenzweig EB, Morse JH, Knowles JA. , et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27 (06) 668-674
- 48 Elliott CG, Glissmeyer EW, Havlena GT. , et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 2006; 113 (21) 2509-2515
- 49 Sztrymf B, Coulet F, Girerd B. , et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177 (12) 1377-1383
- 50 Girerd B, Coulet F, Jaïs X. , et al. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. Chest 2015; 147 (05) 1385-1394
- 51 Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci 2017
- 52 Thomson J, Machado R, Pauciulo M. , et al. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein type II receptor. J Heart Lung Transplant 2001; 20 (02) 149
- 53 Machado RD, Pauciulo MW, Thomson JR. , et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68 (01) 92-102
- 54 Maquat LE. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol 2004; 5 (02) 89-99
- 55 Cogan JD, Pauciulo MW, Batchman AP. , et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174 (05) 590-598
- 56 Cogan JD, Vnencak-Jones CL, Phillips III JA. , et al. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 2005; 7 (03) 169-174
- 57 Cogan J, Austin E, Hedges L. , et al. Role of BMPR2 alternative splicing in heritable pulmonary arterial hypertension penetrance. Circulation 2012; 126 (15) 1907-1916
- 58 Rudarakanchana N, Flanagan JA, Chen H. , et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002; 11 (13) 1517-1525
- 59 Hamid R, Cogan JD, Hedges LK. , et al. Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele. Hum Mutat 2009; 30 (04) 649-654
- 60 Atkinson C, Stewart S, Upton PD. , et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105 (14) 1672-1678
- 61 Cogan J, Austin E, Hedges L. , et al. Role of BMPR2 alternative splicing in heritable pulmonary arterial hypertension penetrance. Circulation 2012; 126 (15) 1907-1916
- 62 West J, Austin E, Fessel JP, Loyd J, Hamid R. Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension. Drug Discov Today 2014; 19 (08) 1241-1245
- 63 Spiekerkoetter E, Tian X, Cai J. , et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 2013; 123 (08) 3600-3613
- 64 Spiekerkoetter E, Sung YK, Sudheendra D. , et al. Low-dose FK506 (Tacrolimus) in end-stage pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192 (02) 254-257
- 65 Viales RR, Eichstaedt CA, Ehlken N. , et al. Mutation in BMPR2 promoter: a ‘second hit’ for manifestation of pulmonary arterial hypertension?. PLoS One 2015; 10 (07) e0133042
- 66 Maloney JP, Stearman RS, Bull TM. , et al. Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2012; 302 (06) L541-L554
- 67 Pierpont ME, Basson CT, Benson Jr DW. , et al; American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115 (23) 3015-3038
- 68 Germain M, Eyries M, Montani D. , et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet 2013; 45 (05) 518-521
- 69 Girerd B, Montani D, Coulet F. , et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010; 181 (08) 851-861
- 70 Ghigna MR, Guignabert C, Montani D. , et al. BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. Eur Respir J 2016; 48 (06) 1668-1681
- 71 van der Bruggen CE, Happé CM, Dorfmüller P. , et al. Bone morphogenetic protein receptor type 2 mutation in pulmonary arterial hypertension: a view on the right ventricle. Circulation 2016; 133 (18) 1747-1760
- 72 Harper RL, Reynolds AM, Bonder CS, Reynolds PN. BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling. Respirology 2016; 21 (04) 727-733
- 73 Brewington J, Clancy JP. Diagnostic testing in cystic fibrosis. Clin Chest Med 2016; 37 (01) 31-46
- 74 Girerd B, Montani D, Jaïs X. , et al. Genetic counselling in a national referral centre for pulmonary hypertension. Eur Respir J 2016; 47 (02) 541-552
- 75 Frydman N, Steffann J, Girerd B. , et al. Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. Eur Respir J 2012; 39 (06) 1534-1535